WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) reported third-quarter results that highlight accelerating commercial traction for its lead product, YCANTH®, alongside major regulatory and clinical milestones that broaden the company’s late-stage dermatology pipeline.
The company posted $14.3 million in revenue for the quarter ended September 30, 2025, including $3.6 million from YCANTH and $10.7 million from license and collaboration agreements. Growth in YCANTH adoption continues to be a central driver, supported by strong physician uptake and international progress.
CEO Jayson Rieger said the quarter marked meaningful steps forward across the business. “Verrica achieved multiple commercial, corporate, scientific and regulatory milestones providing a strong foundation for future growth in YCANTH as well as significant upside potential from our late-stage clinical pipeline,” he said.
For the nine-month period, Verrica dispensed 37,642 applicator units of YCANTH, more than double the 17,119 units dispensed a year earlier. The expansion came while the company reduced operating expenses by nearly 50 percent.
YCANTH’s global footprint also expanded. Verrica recorded a $10 million milestone payment linked to the therapy’s approval for molluscum in Japan, achieved with development partner Torii Pharmaceutical. In Europe, the company received positive feedback from the European Medicines Agency, clearing a pathway to file a Marketing Authorization Application for molluscum without additional Phase 3 studies.
Domestically, Verrica advanced its broader development pipeline. The FDA provided positive guidance and alignment on the Phase 3 study design for VP-315, its oncology candidate for basal cell carcinoma. New data for the therapy was presented at the Society for Immunotherapy of Cancer conference, underscoring scientific interest in the program.
The company also initiated a global Phase 3 clinical program for YCANTH (VP-102) in common warts, with first patient enrollment in the United States targeted for this year. Together, these developments position Verrica with one of the most comprehensive late-stage portfolios in medical dermatology.
Rieger emphasized the growing recognition of Verrica’s pipeline at recent scientific and business gatherings, noting increased partnering discussions and potential opportunities for non-dilutive financing to support future development.
With revenue gains, international regulatory progress, and clear advancement in both its dermatology and oncology programs, Verrica enters the final stretch of 2025 with expanding momentum and a strengthened outlook for 2026.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.